# Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Source: https://onco.cc/trials/nct04514419/  
OnCo record `nct04514419` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pertuzumab in advanced solid tumours, run by BioRay Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel is a phase 3 interventional study registered as NCT04514419 by BioRay Pharmaceutical Co., Ltd., with 408 participants enrolled, started 2020-06-28 and due to reach its primary completion in 2024-09-11. Interventions recorded: HS627 and Pertuzumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04514419
- Phase: 3
- Setting: A Phase III Study to Compare HS627 vs. Pertuzumab on the Efficacy, Safety and Immunogenicity in Combination With Trastuzumab and Docetaxel as Neoadjuvant Therapy in Patients With Early-stage or Locally Advanced HER2 Positive Breast Cancer
- Sponsor: BioRay Pharmaceutical Co., Ltd.
- Enrolled: 408

## Sources

- ClinicalTrials.gov NCT04514419: https://clinicaltrials.gov/study/NCT04514419

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pertuzumab](https://onco.cc/drugs/pertuzumab/)

---
JSON: https://onco.cc/api/v1/entities/nct04514419.json